Erythropoietin combined with ace inhibitor prevents heart Remodeling in 5/6 Nephrectomized rats independently of blood pressure and kidney function

American Journal of Nephrology

Volumn 38, Issue 2, 2013, Pages 124-135

  Gut, Nadezda ^a,b   Piecha, Grzegorz ^e   Aldebssi, Firas ^b   Schaefer, Sebastian ^b   Bekeredjian, Raffi ^c   Schirmacher, Peter ^b   Ritz, Eberhard ^d   Gross Weissmann, Marie Luise ^b  

^a MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^b Institute of Pathology   (Germany)

^c Department of Cardiology ^*  (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

ACE inhibitor; Erythropoietin; Heart failure; Hypertension; Oxidative stress

Indexed keywords

ALBUMIN; CREATININE; DIHYDRALAZINE; ENALAPRIL; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULOSCLEROSIS; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART REMODELING; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; ALBUMINURIA; ANEMIA; ANIMAL CELL; ARTERIAL WALL THICKNESS; BLOOD PRESSURE MEASUREMENT; CAPILLARY DENSITY; CHRONIC KIDNEY DISEASE; HEART PROTECTION; HYPOXEMIA; IN VIVO STUDY; KIDNEY FIBROSIS; MONOTHERAPY; PLEIOTROPY; PROTEIN EXPRESSION; RETICULOCYTE COUNT; SHAM PROCEDURE; STEREOLOGY; SYSTEMATIC REVIEW; WESTERN BLOTTING;

ALBUMINS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; APOPTOSIS; BLOOD PRESSURE; DRUG SYNERGISM; ECHOCARDIOGRAPHY; ENALAPRIL; ERYTHROPOIETIN; FIBROSIS; HEART; HEART RATE; HEMOGLOBINS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MICROCIRCULATION; MYOCARDIUM; NEPHRECTOMY; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84880972758     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000353106     Document Type: Article

References (61)

1. Caskey FJ, Schober-Halstenberg HJ, Roderick PJ, Edenharter G, Ansell D, Frei U, Feest TG: Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am J Kidney Dis 2006; 47: 445-454.
2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
3. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/ capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9: 1018-1022.
4. Smith KJ, Bleyer AJ, Little WC, Sane DC: The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59: 538-548.
5. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helixloop- helix-PAS heterodimer regulated by cellular O 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
6. Chong ZZ, Kang JQ, Maiese K: Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002; 11: 863-871.
7. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
8. Greaves SC, Gamble GD, Collins JF, Whalley GA, Sharpe DN: Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 1994; 24: 768-776.
9. Alexander M, Kewalramani R, Agodoa I, Globe D: Association of anemia correction with health-related quality of life in patients not on dialysis. Curr Med Res Opin 2007; 23: 2997-3008.
10. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 2010; 362: 189-192.
11. Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-745.
12. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
13. Amann K, Buzello M, Simonaviciene A, Miltenberger- Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E: Capillary/ myocyte mismatch in the heart in renal failure - a role for erythropoietin? Nephrol Dial Transplant 2000; 15: 964-969.
14. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH: Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64: 326-333.
15. Furlani D, Klopsch C, Gabel R, Ugurlucan M, Pittermann E, Klee D, Wagner K, Li W, Wang W, Ong LL, Nizze H, Titze U, Lutzow K, Lendlein A, Steinhoff G, Ma N: Intracardiac erythropoietin injection reveals anti-inflammatory potential and improved cardiac functions detected by forced swim test. Transplant Proc 2008; 40: 962-966.
16. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M: Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 2011; 82: 1291-1303.
17. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806.
18. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross M-L: Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 2008; 294:F748-F757.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
20. Amann K, Munter K, Wessels S, Wagner J, Balajew V, Hergenroder S, Mall G, Ritz E: Endothelin a receptor blockade prevents capillary/ myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 2000; 11: 1702-1711.
21. Henquell L, Honig C: Intercapillary distances and capillary reserve in right and left ventricles: significance for control of tissue pO 2 . Microvasc Res 1976; 12: 35-41.
22. Amann K, Tornig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E: Blood-pressureindependent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant 1995; 10: 2043-2048.
23. Van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ: Erythropoietin in cardiovascular diseases. Eur Heart J 2004; 25: 285-291.
24. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210.
25. Conlon PJ, Albers F, Butterly D, Schwab SJ: Ace inhibitors do not affect erythropoietin efficacy in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 1358.
26. Hess E, Sperschneider H, Stein G: Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996; 11: 749-751.
27. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
28. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
29. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
30. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B: 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
31. Roger SD, Fluck RJ, McMahon AC, Raine AE: Recombinant erythropoietin increases blood pressure in experimental hypertension and uraemia without change in vascular cytosolic calcium. Nephron 1996; 73: 212-218.
32. Janssen WM, de Jong PE, de Zeeuw D: Hypertension and renal disease: role of microalbuminuria. J Hypertens Suppl 1996; 14:S173-177.
33. Silverberg DS, Wexler D, Iaina A: The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002; 4: 681-686.
34. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
35. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619.
36. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D: Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006; 17: 2293-2298.
37. Fishbane S: Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 2008; 4: 401-410.
38. Silverberg DS, Wexler D, Iaina A, Schwartz D: The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26: 296-306.
39. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G: Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992; 42: 1079-1085.
40. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982.
41. Nagai T, Akizawa T, Nakashima Y, Kohjiro S, Nabeshima K, Kanamori N, Takayama K, Kinugasa E, Koshikawa S: Effects of rHuEPO on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 1995; 10: 1814-1819.
42. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML: Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest 2009; 89: 520-530.
43. Maschio G: Erythropoietin and systemic hypertension. Nephrol Dial Transplant 1995; 10(suppl 2):74-79.
44. Burger D, Xenocostas A, Feng QP: Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharmacol 2009; 2: 56-69.
45. Van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG: Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46: 125-133.
46. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M: Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101: 31-39.
47. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H: Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71: 684-694.
48. Wassmann S, Nickenig G: Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 2006; 24:S15-S21.
49. Amann K, Wolf B, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E: Aortic changes in experimental renal failure: hyperplasia or hypertrophy of smooth muscle cells? Hypertension 1997; 29: 770-775.
50. Ben Driss A, Himbert C, Poitevin P, Duriez M, Michel JB, Levy BI: Enalapril improves arterial elastic properties in rats with myocardial infarction. J Cardiovasc Pharmacol 1999; 34: 102-107.
51. Heyman SN, Khamaisi M, Rosen S, Rosenberger C: Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008; 28: 998-1006.
52. Berl T, Henrich W: Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.
53. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG: Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000; 59: 419-425.
54. Cheng TH, Cheng PY, Shih NL, Chen IB, Wang DL, Chen JJ: Involvement of reactive oxygen species in angiotensin II-induced endothelin- 1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol 2003; 42: 1845-1854.
55. Siwik DA, Pagano PJ, Colucci WS: Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280:C53-C60.
56. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
57. Gustafsson AB, Gottlieb RA: Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol 2007; 292:C45-C51.
58. Murriel CL, Churchill E, Inagaki K, Szweda LI, Mochly-Rosen D: Protein kinase C? activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving bad and the mitochondria. J Biol Chem 2004; 279: 47985-47991.
59. Chong ZZ, Kang JQ, Maiese K: Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-2979.
60. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003; 308: 990-994.
61. Goussev A, Sharov VG, Shimoyama H, Tanimura M, Lesch M, Goldstein S, Sabbah HN: Effects of ace inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol 1998; 275:H626-H631.